Raymond James & Associates’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2024
Q3
$5.29M Sell
264,392
-13,835
-5% -$277K ﹤0.01% 1620
2024
Q2
$3.11M Sell
278,227
-5,966
-2% -$66.7K ﹤0.01% 1893
2024
Q1
$1.88M Buy
284,193
+34,897
+14% +$230K ﹤0.01% 2193
2023
Q4
$1.13M Buy
249,296
+5,657
+2% +$25.6K ﹤0.01% 2434
2023
Q3
$872K Buy
243,639
+10,018
+4% +$35.9K ﹤0.01% 2536
2023
Q2
$862K Sell
233,621
-8,255
-3% -$30.5K ﹤0.01% 2553
2023
Q1
$801K Buy
241,876
+5,023
+2% +$16.6K ﹤0.01% 2590
2022
Q4
$919K Sell
236,853
-15,720
-6% -$61K ﹤0.01% 2472
2022
Q3
$614K Sell
252,573
-16,083
-6% -$39.1K ﹤0.01% 2716
2022
Q2
$532K Buy
268,656
+68,672
+34% +$136K ﹤0.01% 2865
2022
Q1
$366K Buy
199,984
+38,715
+24% +$70.9K ﹤0.01% 3251
2021
Q4
$227K Buy
161,269
+9,086
+6% +$12.8K ﹤0.01% 3592
2021
Q3
$172K Buy
152,183
+29,029
+24% +$32.8K ﹤0.01% 3673
2021
Q2
$197K Sell
123,154
-56,337
-31% -$90.1K ﹤0.01% 3661
2021
Q1
$316K Buy
179,491
+43,202
+32% +$76.1K ﹤0.01% 3304
2020
Q4
$266K Sell
136,289
-45,362
-25% -$88.5K ﹤0.01% 3168
2020
Q3
$434K Sell
181,651
-76,813
-30% -$184K ﹤0.01% 2720
2020
Q2
$757K Buy
258,464
+34,674
+15% +$102K ﹤0.01% 2324
2020
Q1
$645K Buy
223,790
+103,545
+86% +$298K ﹤0.01% 2245
2019
Q4
$481K Buy
120,245
+70,188
+140% +$281K ﹤0.01% 2748
2019
Q3
$223K Buy
50,057
+806
+2% +$3.59K ﹤0.01% 3167
2019
Q2
$191K Buy
49,251
+34,531
+235% +$134K ﹤0.01% 3254
2019
Q1
$56K Sell
14,720
-12,151
-45% -$46.2K ﹤0.01% 3419
2018
Q4
$64K Buy
26,871
+10,610
+65% +$25.3K ﹤0.01% 3333
2018
Q3
$101K Sell
16,261
-5,059
-24% -$31.4K ﹤0.01% 3394
2018
Q2
$96K Buy
+21,320
New +$96K ﹤0.01% 3370
2016
Q3
Sell
-10,891
Closed -$65K 3069
2016
Q2
$65K Buy
+10,891
New +$65K ﹤0.01% 2824